by Takeda UK and Ireland with support from Apodi Limited
Takeda and Apodi have developed and deployed a Support Programme for Patients prescribed NINLARO which is fully aligned with Takeda’s core values and Apodi’s model for patient-centricity
The programme is delivered by experienced NINLARO Specialist Nurses (NSNs), who provide incremental and integrated capacity to NHS units, and deliver high levels of quality patient interactions which can take place in clinic, on the telephone, in the patient’s home, or any combination of these.
At participating hospitals, every NINLARO patient has a named NSN, together with a tailored support plan aligned with their preferences. This drives continuity of care, the best possible experiences and outcomes and helps them, and their Healthcare Professionals (HCPs) to identify and manage toxicities early, thus driving appropriate time on therapy.
The PSP is supported by educational literature for both patients and HCPs which is designed to drive knowledge and confidence in treatment and management.
Feedback from both patients and HCPs demonstrates that the programme is having positive effects on treatment outcomes and is highly valued.
The Programme at each Trust is reviewed regularly by Senior Management at Takeda, Apodi and the Trust to ensure high levels of performance and a culture of continuous improvement.
This entry from Takeda and Apodi was quite simply phenomenal! It is a fabulous patient support programme with good insight, clear and well measured objectives and successful outcomes.
Entry deadline | 27 August 2020 |
Extended entry deadline | 3 September 2020* *additional fee applies |
Judging Day | 1 October 2020 |
Company of the Year Interviews | 22 October 2020 |
PMEA Event | 25 November 2020 |